|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P429
|
Nanoparticle Based Enrichment and Expansion of Self and Neo-epitope Specific CD8+ T cells in Murine Melanoma
|
Catherine A Bessell1, Joan Glick Bieler1, John-William Sidhom1, Jonathan P Schneck1
|
1Johns Hopkins University, Baltimore, MD, USA
|
Tumor antigens | Neoantigens | T cell
|
|
P430
|
Neoantigen identification using ATLASTM across multiple tumor types highlights limitations of prediction algorithms
|
Jason Dobson1, Huilei Xu1, Kyle Ferber1, Johanna Kaufmann1, Judy Jacques1, Christine McCoy1, Michael O'Keeffe1, Yana Ostrovsky1, Crystal Cabral1, Pamela Carroll1, Theresa Zhang1, Jessica Flechtner1, Wendy Broom1
|
1Genocea Biosciences, Cambridge, MA, USA
|
Cytokine | Neoantigens | T cell | Vaccine | Tumor antigens | Targeted therapy | Monocyte/Macrophage
|
|
P431
|
Identification of immunogenic breast cancer neoantigens exposed by radiation therapy
|
Claire Lhuillier1, Nils Rudqvist1, Takahiro Yamazaki1, Tuo Zhang1, Lorenzo Galluzzi1, Sandra Demaria1
|
1Weill Cornell Medical College, New-York, NY, USA
|
Tumor antigens | Neoantigens | Checkpoint blockade | Solid tumors | Radiotherapy | Gene expression | Tumor infiltrating lymphocytes (TILs)
|
|
P432
|
Exploiting large scale HLA peptidomics to generate novel Immunotherapies; A data-driven approach to neoantigen prioritisation
|
Alex S. Powlesland1, Geert P.M. Mommen1, Ricardo J. Carreira1, David Lowne1, Michael J. Cundell1, Floriana Capuano1, Bent K. Jakobsen1
|
1Immunocore Ltd, Abingdon, United Kingdom
|
Neoantigens | Proteomics | Tumor antigens | T cell | Bioinformatics | Targeted therapy | Vaccine | Adoptive immunotherapy
|
|
P433
|
Computational pipeline for the PGV-001 (personalized genomic vaccine) clinical trial
|
Alexander Rubinsteyn1, Julia Kodysh2, Nina Bhardwaj1, Jeffrey Hammerbacher1
|
1Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Icahn School of Medicine, New York, NY, USA
|
Bioinformatics | Clinical study | Neoantigens | Vaccine
|
|
P434
|
Great Apes Adenoviral vaccine encoding neoantigens synergizes with immunomodulators to cure established tumors in mice
|
Anna Morena D'Alise1, Gabriella Cotugno2, Guido Leoni2, Francesaca Langone2, Imma Fichera2, Maria De Lucia2, Rosa Vitale2, Adriano Leuzzi2, Elena Di Matteo2, Antonella Folgori2, Stefano Colloca2, Alfredo Nicosia2, Jonathan Zalevsky2, Elisa Scarselli2
|
Nouscom srl1, Nektar Therapeutics2
|
Neoantigens, Tumor Antigens, Cytokine, T cell, Tumor Infiltrating, Vaccine
|
|
P435
|
Immunogenomics for the development of personalized T cell therapy for ovarian cancer
|
Muzamil Want1, Sebastiano Battaglia1, Takemasa Tsuji1, Richard Koya1 |
Roswell Park Cancer Institute1 |
Adoptive Immunotherapy, Bioinformatics, Neoantigens, Targeted therapy, Solid Tumors |
|
P436
|
In vivo self-assembled albumin/vaccine nanocomplexes for lymph-node-targeted vaccine delivery in combination cancer immunotherapy
|
Guizhi Zhu1, Xiaoyuan Chen1
|
1National Institutes of Health, Bethesda, MD, USA
|
Tumor antigens | Neoantigens | Checkpoint blockade | Vaccine | Immune adjuvant
|